 |
|
| Blog results | Results 1 - 10 of about 522 for bisphosphonates or raloxifene. (0.32 seconds) |
| Sorted by relevance Sort by date |
| 13 Feb 2008 by ron The bisphosphonates and raloxifene are antiresorptive agents that have been proven to increase bone mineral density and decrease fractures. These agents are considered to be the therapy of choice in prevention and treatment of ... Osteoporosis Care Center - http://osteoporosis-care-center.blogspot.com/ |
| 17 Dec 2009 by By Martha Rosenberg SERMs, like tamoxifen and Evista (raloxifene), could help mammogram readability and even prevent or treat breast cancer, except they increased the risk of endometrial and ovarian cancer. Anyone see where this is going? ... But the women on bisphosphonates, in the paper presented at the Annual San Antonio Breast Cancer Symposium, were also more likely to get noninvasive breast cancer called ductal carcinoma in situ (DCIS). This is not the only example of the choice given ... Epoch Times | All headlines - http://www.theepochtimes.com/ - References |
| 7 Dec 2009 by Medical and Fitness While there is currently no clear evidence that you should stop taking bisphosphonates before dental surgery, let your dentist know what medications you're taking and discuss your concerns. Raloxifene (Evista). ... Medical adv - http://medicaladv.blogspot.com/ |
| 30 Oct 2009 Osteoporosis International. Pulmonology News - http://www.mdlinx.com/InternalMDLinx/news.cfm/newspage/1/spec_id/3/subspec_id/13 |
| 16 Dec 2009 by ujvali The only medications approved now for the prevention of breast cancer in healthy women at higher risk are the hormone blockers raloxifene and tamoxifen. The side effects for these medications are high blood pressure, hot flashes and a ... cancer - http://cancerdesk.blogspot.com/ |
| 13 Dec 2009 by Dr. NICK He noted that a similar finding was seen in the STAR trial of tamoxifen and raloxifene; however, the marginally statistically significant increase in DCIS that was seen in that trial "has not played out as an increase in invasive breast ... CANCER AND IMPORTANT MEDICAL NEWS - http://cancerology.blogspot.com/ |
| 11 Dec 2009 by Jacklou59 The only drugs approved now for preventing breast cancer in healthy women at higher risk are the hormone blockers tamoxifen and raloxifene. Side effects such as hot flashes, high blood pressure and a higher risk of blood clots have ... Trackpads Community - http://www.trackpads.com/forum/ |
| 11 Nov 2009 by salud equitativa Based on limited data from head-to-head trials, superiority for the prevention of vertebral fractures has not been demonstrated for bisphosphonates in comparison with calcitonin, calcium, or raloxifene. However, these studies were not ... CIENCIASMEDICASNEWS - http://elbiruniblogspotcom.blogspot.com/ |
| 27 Oct 2009 by Hall, L. N, Shrader, S. P, Ragucci, K. R ... medication use), fracture history, baseline and follow-up DEXA scans and results, pharmacotherapy (bisphosphonates, calcitonin, raloxifene, teriparatide), calcium and vitamin D supplementation, and nonpharmacologic education. ... Annals of Pharmacotherapy current issue - http://www.theannals.com/ [ More results from Annals of Pharmacotherapy current issue ] |
| 11 Jun 2008 by Effective Health Care - Agency for Healthcare... Raloxifene, tamoxifen, and estrogen increase the risk of thromboembolic events. Level of confidence: High. It is unknown whether bisphosphonates work better to prevent fractures than any other osteoporosis treatments. ... Effective Health Care - http://effectivehealthcare.ahrq.gov/ - References [ More results from Effective Health Care ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
